This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs. MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors. Life-threatening reactions and death have occurred in people who took MDMA while on ritonavir. Bupropion, a strong CYP2D6 inhibitor, has been found to increase MDMA exposure with administration of MDMA. Concurrent use of MDMA with certain other serotonergic drugs can result in a life-threatening condition called serotonin syndrome. Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors (MAOIs), such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix). Serotonin reuptake inhibitors (SRIs) such as citalopram (Celexa), duloxetine (Cymbalta), fluoxetine (Prozac), and paroxetine (Paxil) have been shown to block most of the subjective effects of MDMA. Norepinephrine reuptake inhibitors (NRIs) such as reboxetine (Edronax) have been found to reduce emotional excitation and feelings of stimulation with MDMA but do not appear to influence its entactogenic or mood-elevating effects. MDMA induces the release of monoamine neurotransmitters and thereby acts as an indirectly acting sympathomimetic and produces a variety of cardiostimulant effects. It dose-dependently increases heart rate, blood pressure, and cardiac output.
=== „Kurzmitteilung“ (2014) === Kurzmitteilung [Text Message] is Kermani's first text that he classified as a novel. It is dedicated to the Cologne actress Claudia Fenner, who died of a stroke in July 2005 at the age of 40. In the novel, Maike Anfang, who worked for Ford, dies on the same date and just as unexpectedly. She was supposed to organize an event together with the first-person narrator Dariusch, a freelance event manager. The initiating event of the novel is the text message that gives the book its title, in which Dariusch learns of the sudden death of Maike Anfang, whom he met only fleetingly, while on vacation. The novel narrates the first few days after Maike Anfang’s death, with the question of how to communicate appropriately about death serving as a leitmotif. The protagonist, Dariusch, is less affected by the personal loss than by the sudden confrontation with his own mortality. Although he is able to speak to the relatives of the deceased in an educated and empathetic manner, he is presented as a caricature of a dim-witted, sex-obsessed macho who ends up going on and on about his experience of an awakening in a self-discovery center in the United States.
== Abstracting and indexing == The journal is abstracted and indexed in Chemical Abstracts, Current Contents/Clinical Medicine, Index Medicus/MEDLINE/PubMed, Science Citation Index Expanded, and Scopus. According to the Journal Citation Reports, the journal has a 2015 impact factor of 1.224.
== Solid-phase peptide synthesis (SPPS) == Solid-phase synthesis is a common technique for peptide synthesis. Usually, peptides are synthesised from the carbonyl group side (C-terminus) to amino group side (N-terminus) of the amino acid chain in the SPPS method, although peptides are biologically synthesised in the opposite direction in cells. In peptide synthesis, an amino-protected amino acid is bound to a solid phase material or resin (most commonly, low cross-linked polystyrene beads), forming a covalent bond between the carbonyl group and the resin, most often an amido or an ester bond. Then the amino group is deprotected and reacted with the carbonyl group of the next N-protected amino acid. The solid phase now bears a dipeptide. This cycle is repeated to form the desired peptide chain. After all reactions are complete, the synthesised peptide is cleaved from the bead. The protecting groups for the amino groups mostly used in the peptide synthesis are 9-fluorenylmethyloxycarbonyl group (Fmoc) and t-butyloxycarbonyl (Boc). A number of amino acids bear functional groups in the side chain which must be protected specifically from reacting with the incoming N-protected amino acids. In contrast to Boc and Fmoc groups, these have to be stable over the course of peptide synthesis although they are also removed during the final deprotection of peptides.
Sources: en.wikipedia.org
== History == Results of a Phase I clinical trial were reported in 2016. In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy. The approval was based on the results of a clinical trial of 125 such patients. The overall response rate, reflecting the percentage of patients who had a certain amount of tumor shrinkage, was 44%; specifically, 12% had a complete response and 32% a partial response. The median duration of response was 7.6 months. The U.S. Food and Drug Administration (FDA) granted the application for enfortumab vedotin accelerated approval, priority review designation, and breakthrough therapy designation. The FDA granted the approval of Padcev to Astellas Pharma US Inc. In July 2021, the FDA approved enfortumab vedotin for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received therapy.
They rose up to defend the rights and status that they had received as Indians from the colonial power, and that the criollo republic threatened to liquidate. On the other hand, it has been pointed out that he gave instructions to the army of Greater Colombia, during the Peruvian War of Independence, to carry out looting and other kinds of harassment against the Peruvian population, under the excuse that in times of war it was necessary to act dictatorially, giving extraordinary powers to the militia, and showing indifference to serious cases of corruption, of which Bolívar, instead of executing them, would rather have been in charge of distributing said loot (to avoid conflict between his caudillos) of the Peruvian victims to the looting of their properties. Only in the province of Lambayeque, which was not one of the richest, the amount of 500,000 pesos was extracted in 1824, by quotas and confiscations. In addition to the fact that he came to dismiss Peruvians like Andrés de los Reyes, due to his protests that he gave for Bolívar's orders to loot churches. The discomfort caused by the looting of the Colombians made the indigenous guerrilla Ninavilca exclaim from the four winds that the Colombians were "una chusma de ladrones" [a mob of thieves] who plundered Peruvian resources, and once the conflict ended they did not become more popular, generating an Anti-Colombian (included anti-venezolan) feeling in Peru. "Not only did Bolívar transfer his dictatorial power to Heres.
=== Surgery === A randomized controlled trial found that surgery "reduces the recurrence of ulcers at four years and results in a greater proportion of ulcer free time". Local anaesthetic endovenous surgery using the thermoablation (endovenous laser ablation or radiofrequency), perforator closure (TRLOP) and foam sclerotherapy showed an 85% success rate of healing, with no recurrence of healed ulcers at an average of 3.1 years, and a clinical improvement in 98% in a selected group of venous leg ulcers. Endovenous ablation, in combination with compression, on superficial venous incompetence has been shown (high-quality evidence) to improve leg ulcer healing when compared to compression alone. The use of subfascial endoscopic perforator surgery is uncertain in the healing of venous ulcers.
Sources: en.wikipedia.org
=== 1870s === 1869/1870: American beekeeper Ellen Smith Tupper became the first female editor of an entomological journal. 1870: Katharine Murray Lyell was a British botanist, author of an early book on the worldwide distribution of ferns, and editor of volumes of the correspondence of several of the era's notable scientists. 1870: American engineer and chemist Ellen Swallow Richards became the first American woman to earn a degree in chemistry. 1870: Russian chemist Anna Volkova became the first female member of the Russian Chemical Society. 1874: Russian chemist Julia Lermontova became the first Russian woman to receive a PhD in chemistry. 1875: Hungarian archaeologist Zsófia Torma excavated the site of Turdaș-Luncă in Hunedoara County, today in Romania. The site, which uncovered valuable prehistoric artifacts, became one of the most important archaeological discoveries in Europe. 1876–1878: American naturalist Mary Treat studied insectivorous plants in Florida. Her contributions to the scientific understanding of how these plants caught and digested prey were acknowledged by Charles Darwin and Asa Gray. 1878: English entomologist Eleanor Anne Ormerod became the first female Fellow of the Royal Meteorological Society. A few years afterwards, she was appointed as Consulting Entomologist to the Royal Agricultural Society.
=== July === 1 July – Balmoral Castle opens to the public for tours for the first time, with daily tours running until 4 August. Steve Carson is to step down as Head of Multi-Platform Commissioning at BBC Scotland in September, in order to take up a senior role at Irish broadcaster RTÉ. 2 July – After rejecting a pay offer in May, waste and recycling staff belonging to Unite in half of Scotland's councils vote to strike. 3 July – Queen Camilla and Prince Edward are formally appointed to the Order of the Thistle at a ceremony in Edinburgh. Moray Council is ordered to pay £346,000 in compensation to a foster family who were wrongly accused of "sexual impropriety" involving children they fostered during the 2010s. 5 July – 2024 United Kingdom general election in Scotland: The SNP suffers heavy losses, going from 48 seats to just nine. With 56 of the 57 seats contested in Scotland declared, Labour win 37, the SNP win nine, while the Conservatives and Liberal Democrats each win five. Starmer ministry: The incoming Labour prime minister Keir Starmer appoints Ian Murray as Secretary of State for Scotland. 6 June – 2024 United Kingdom general election in Scotland: Inverness, Skye and West Ross-shire becomes the final constituency to declare its election results, and sees the number of Liberal Democrat MPs rise to 6 in Scotland after they defeat the SNP to win the seat.
Different cell types within adipose tissue exhibit distinct DNA methylation patterns. Mature adipocytes and adipose progenitor cells (ASPCs) show a high degree of hypomethylation, affecting more than 50% of their regulatory regions. This hypomethylation is associated with the activation of genes involved in triglyceride synthesis, such as glycerol‑3‑phosphate acyltransferase 1 (GPAM). In contrast, myeloid cells display approximately 73% hypermethylated regions, reflecting an epigenetic program opposite to that of the adipocytic lineage. Overall, there is a direct relationship between DNA demethylation and gene expression, whereby highly expressed genes tend to exhibit low methylation levels. These epigenetic patterns contribute to defining the functional identity of the different cell types within subcutaneous adipose tissue (SAT).
== Signs and symptoms == Generally, the majority of individuals with creatine transporter defect express the following symptoms with varying levels of severity: developmental delay and regression, intellectual disability, and abnormalities in expressive and cognitive speech. However, several studies have shown a wider variety of symptoms including, but not limited to attention deficit and hyperactivity with impulsivity, myopathy, hypotonia, semantic-pragmatic language disorder, oral dyspraxia, extrapyramidal movement disorder, constipation, absent speech development, seizures, and epilepsy. Furthermore, symptoms can significantly vary between hemizygous males and heterozygous females, although, symptoms are generally more severe in hemizygous males. Hemizygous males more commonly express seizures, growth deficiency, severe intellectual disability, and severe expressive language impairment. Heterozygous females more commonly express mild intellectual disability, impairments to confrontational naming and verbal memory, and learning and behavior problems.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.